{"id":38401,"date":"2025-08-01T17:48:49","date_gmt":"2025-08-01T09:48:49","guid":{"rendered":"https:\/\/flcube.com\/?p=38401"},"modified":"2025-08-01T17:48:50","modified_gmt":"2025-08-01T09:48:50","slug":"abbvie-reports-strong-q2-2025-results-with-immunology-portfolio-leading-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38401","title":{"rendered":"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth"},"content":{"rendered":"\n<p>US-based multinational AbbVie Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) reported strong Q2 2025 results with global revenues increasing by 6.5% year-on-year (YOY) to USD 15.42 billion. CEO Robert A. Michael highlighted that the results &#8220;exceeding our expectations&#8221; and announced a raise in the firm\u2019s full-year guidance by USD 1.5 billion to USD 60.5 billion.<\/p>\n\n\n\n<p><strong>Immunology Portfolio Drives Growth<\/strong><br>The immunology portfolio recorded a 9.2% sales increase to USD 7.63 billion, supported by significant growth from two key autoimmune disease drugs:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Skyrizi (risankizumab)<\/strong>: Targeting interleukin-23 (IL-23), sales surged by 61.8% to USD 4.42 billion.<\/li>\n\n\n\n<li><strong>Rinvoq (upadacitinib)<\/strong>: A JAK inhibitor, sales rose by 41.2% to USD 2.03 billion.<\/li>\n<\/ul>\n\n\n\n<p>These gains helped offset the 58.2% sales decline for off-patent <strong>Humira (adalimumab)<\/strong>, which recorded USD 1.18 billion in sales.<\/p>\n\n\n\n<p><strong>Neuroscience Portfolio Highlights<\/strong><br>The neuroscience portfolio saw a 23% increase in sales to USD 2.683 billion, driven by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vraylar (cariprazine)<\/strong>: Anti-depressant sales up 16.3% to USD 900 million.<\/li>\n\n\n\n<li><strong>Botox Therapeutic<\/strong>: Botulinum toxin sales up 14.2% to USD 928 million.<\/li>\n\n\n\n<li><strong>Ubrelvy (ubrogepant)<\/strong>: Migraine treatment sales up 47.2% to USD 338 million.<\/li>\n\n\n\n<li><strong>Qulipta (atogepant)<\/strong>: Migraine drug revenues up 76.9% to USD 267 million.<\/li>\n<\/ul>\n\n\n\n<p><strong>Oncology and Aesthetics Portfolio<\/strong><br>Oncology sales rose by 2.4% to USD 1.68 billion, while the aesthetics portfolio experienced an 8.1% decrease to USD 1.279 billion.<\/p>\n\n\n\n<p><strong>R&amp;D Highlights<\/strong><br>During the earnings call, AbbVie emphasized several key R&amp;D milestones:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Approval of <strong>Emrelis (telisotuzumab vedotin)<\/strong>, a c-Met targeted antibody-drug conjugate (ADC) for non-squamous non-small cell lung cancer.<\/li>\n\n\n\n<li>Approval of <strong>Rinvoq (upadacitinib)<\/strong> for giant cell arteritis.<\/li>\n\n\n\n<li>First regulatory submission for <strong>trenibotulinumtoxinE (TrenibotE)<\/strong> for moderate to severe glabellar lines.<\/li>\n\n\n\n<li>Strong Phase III data from Rinvoq in alopecia areata.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/ABBV-2Q25-Press-Release-Final.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of ABBV 2Q25 Press Release - Final.\"><\/object><a id=\"wp-block-file--media-c5104ca3-6b02-4212-9982-983be460e5f2\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/ABBV-2Q25-Press-Release-Final.pdf\">ABBV 2Q25 Press Release &#8211; Final<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/ABBV-2Q25-Press-Release-Final.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c5104ca3-6b02-4212-9982-983be460e5f2\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38402,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[234,27,853],"class_list":["post-38401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-abbvie","tag-finanical-reports","tag-nyse-abbv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing by 6.5% year-on-year (YOY) to USD 15.42 billion. CEO Robert A. Michael highlighted that the results &quot;exceeding our expectations&quot; and announced a raise in the firm\u2019s full-year guidance by USD 1.5 billion to USD 60.5 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38401\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth\" \/>\n<meta property=\"og:description\" content=\"US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing by 6.5% year-on-year (YOY) to USD 15.42 billion. CEO Robert A. Michael highlighted that the results &quot;exceeding our expectations&quot; and announced a raise in the firm\u2019s full-year guidance by USD 1.5 billion to USD 60.5 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38401\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-01T09:48:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-01T09:48:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0101-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38401#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38401\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth\",\"datePublished\":\"2025-08-01T09:48:49+00:00\",\"dateModified\":\"2025-08-01T09:48:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38401\"},\"wordCount\":265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38401#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0101-1.webp\",\"keywords\":[\"AbbVie\",\"Finanical Reports\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38401#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38401\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38401\",\"name\":\"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38401#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38401#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0101-1.webp\",\"datePublished\":\"2025-08-01T09:48:49+00:00\",\"dateModified\":\"2025-08-01T09:48:50+00:00\",\"description\":\"US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing by 6.5% year-on-year (YOY) to USD 15.42 billion. CEO Robert A. Michael highlighted that the results \\\"exceeding our expectations\\\" and announced a raise in the firm\u2019s full-year guidance by USD 1.5 billion to USD 60.5 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38401#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38401\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38401#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0101-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0101-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38401#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth - Insight, China&#039;s Pharmaceutical Industry","description":"US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing by 6.5% year-on-year (YOY) to USD 15.42 billion. CEO Robert A. Michael highlighted that the results \"exceeding our expectations\" and announced a raise in the firm\u2019s full-year guidance by USD 1.5 billion to USD 60.5 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38401","og_locale":"en_US","og_type":"article","og_title":"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth","og_description":"US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing by 6.5% year-on-year (YOY) to USD 15.42 billion. CEO Robert A. Michael highlighted that the results \"exceeding our expectations\" and announced a raise in the firm\u2019s full-year guidance by USD 1.5 billion to USD 60.5 billion.","og_url":"https:\/\/flcube.com\/?p=38401","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-01T09:48:49+00:00","article_modified_time":"2025-08-01T09:48:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0101-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38401#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38401"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth","datePublished":"2025-08-01T09:48:49+00:00","dateModified":"2025-08-01T09:48:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38401"},"wordCount":265,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38401#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0101-1.webp","keywords":["AbbVie","Finanical Reports","NYSE: ABBV"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38401#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38401","url":"https:\/\/flcube.com\/?p=38401","name":"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38401#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38401#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0101-1.webp","datePublished":"2025-08-01T09:48:49+00:00","dateModified":"2025-08-01T09:48:50+00:00","description":"US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing by 6.5% year-on-year (YOY) to USD 15.42 billion. CEO Robert A. Michael highlighted that the results \"exceeding our expectations\" and announced a raise in the firm\u2019s full-year guidance by USD 1.5 billion to USD 60.5 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38401#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38401"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38401#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0101-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0101-1.webp","width":1080,"height":608,"caption":"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38401#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0101-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38401"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38401\/revisions"}],"predecessor-version":[{"id":38404,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38401\/revisions\/38404"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38402"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}